$ARDT

BofA Securities raised its price target on Ardent Health Partners (ARDT) to $14 from $12, citing the company's acquisition of Boone Health. The stock trades at $17.68, near its 52-week high. BofA expects the deal to add $5M-$10M in EBITDA in the first year, growing to $30M-$40M by the third year. Ardent reported Q3 2026 earnings of $0.31 per share, beating estimates. Mizuho also raised its target to $21, maintaining an Outperform rating.

Ardent Health, Inc. (ARDT) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99 Ardent Health announces definitive agreement to acquire Boone Health • Expands Ardent’s footprint into an attractive mid-sized Missouri market with a scaled health system that generates ~$480 million of annual revenue 1 • Provides $200 million capital commitment over 1

Mizuho raised its price target on Ardent Health Partners (NYSE:ARDT) to $21 from $13, citing improved execution and higher earnings visibility. The stock is up 103% YTD. Ardent reported Q3 2026 adjusted earnings of $0.31 per share, beating estimates, and raised its adjusted EBITDA guidance to $500M-$535M. The company operates hospitals and healthcare facilities in the U.S.

Ardent Health (ARDT) reported Q3 earnings, highlighting a 9% increase in urgent care visits and a 400 basis point decline in physician referral leakage. Labor costs fell 4.3% YoY, and the company plans to sell a Kansas hospital for 11x EBITDA. Ardent generated $122M in Q3 operating cash flow and lowered its 2026 capital expenditure guidance. The company remains 85% contracted for 2027 and 75% for 2028, with negotiations described as contentious.

Stephens & Co. kept Ardent Health at Overweight, raising its price target to $21 from $13, a 61.5% increase. This implies a 32.1% upside from the Nov 5 close of $15.90, according to the firm.

Ardent Health reported Q3 2026 results with total revenue up 3.1% YoY to $1.625B. Net income was $45M, or $0.17 per diluted share, compared to a loss of $23M in Q3 2025. Adjusted EBITDA was $138M. The company raised its 2026 adjusted EBITDA guidance. Adjusted admissions increased 2.9% YoY, while total surgeries decreased 1.9%.

Ardent Health (ARDT) reclassified the departure of CEO Martin J. Bonick as termination for cause, citing failure to disclose third-party compensation. The board's decision, made Oct. 19, 2026, ends Bonick's severance benefits, including $4.5M in cash and unvested PRSUs, effective June 2, 2026.

Ardent Health, Inc. (ARDT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, Martin J. Bonick’s employment as President and Chief Executive Officer of Ardent Health, Inc. (th

BMO Capital initiated coverage on Ardent Health Partners (NYSE:ARDT) with a Market Perform rating and a $11.00 price target. The company's stock trades at $10.95, near the analyst consensus. Ardent reported Q2 2026 adjusted earnings of $0.12 per share, missing estimates but showing strong revenue and cash flow. RBC and Guggenheim raised their price targets to $13.00 and $14.00, respectively, citing strong EBITDA and program benefits.

Ardent Health (ARDT) discussed its Q2 2026 earnings call, citing operational cost reductions under its IMPACT program, including a 42% contract labor spend cut and 0.7% year-over-year SWB growth. It expects 2026 savings to rise to over $70 million and raised adjusted EBITDA outlook by $5 million to $10 million from a June payer renewal. Virtual care via hellocare.ai reported 58% discharge completion in Texas and Idaho.